Velusetrag

Velusetrag belongs to the highly selective, high-affinity generation of 5-HT4 agonists engineered specifically to deliver the prokinetic benefit of the receptor without the cardiac and off-target liabilities that ended cisapride's and tegaserod's careers ^[1]. It shows pan-gastrointestinal activity, accelerating gastric, small-bowel, and colonic transit, which makes it relevant to both constipation and upper-gut motility disorders.

In a multicentre, double-blind, placebo-controlled phase 2b study, 232 subjects with diabetic or idiopathic gastroparesis received velusetrag 5, 15, or 30 mg or placebo for twelve weeks ^[2]. Improvement from baseline in gastric emptying by scintigraphy was greater with velusetrag than placebo across doses, with more than seventy percent of subjects on the 30 mg dose achieving gastric-emptying normalization at four hours; paradoxically, short-term symptom improvement on the Gastroparesis Cardinal Symptom Index was achieved only with the lowest 5 mg dose, and adverse events were generally mild ^[2]. This dissociation between objective emptying and symptom relief is a recurring theme in gastroparesis pharmacology.

Velusetrag has also featured in systematic reviews of highly selective 5-HT4 agonists for chronic constipation, where the class as a whole improved bowel movement frequency and constipation-related quality of life with a favourable safety profile, headache being the most common adverse event ^[3]. Dedicated in vitro cardiovascular work found no significant off-target effect of velusetrag on human coronary artery tone, platelet aggregation, or hERG potassium channel conductance, supporting the selectivity rationale behind its design ^[4].

Across chronic constipation and gastroparesis trials, velusetrag was generally well tolerated, with mostly mild treatment-emergent adverse events; diarrhea, headache, nausea, and abdominal cramping are the expected class effects of enhanced motility. Dedicated cardiovascular studies did not identify hERG channel blockade, coronary constriction, or effects on platelet aggregation, distinguishing it from cisapride and tegaserod. As an investigational agent, its long-term safety across broad populations remains incompletely defined, and higher doses in gastroparesis did not translate into greater symptom relief despite faster emptying.

Velusetrag was discovered at Theravance and designated TD-5108 as part of a deliberate campaign to build selective 5-HT4 agonists that retained prokinetic efficacy while shedding the cardiac risk that led to the withdrawal of cisapride. It advanced through early studies in chronic constipation and was later developed, in collaboration with Alfasigma, for gastroparesis, culminating in a phase 2b trial reported in 2023. It is frequently grouped with prucalopride and naronapride as the vanguard of highly selective, high-affinity 5-HT4 agonists.

In gastroenterology velusetrag is regarded as a well-characterized, cardiac-safe prokinetic that validated the selective 5-HT4 design strategy, even though its gastroparesis results left the dose-response relationship for symptoms unresolved. It is commonly cited in reviews of novel prokinetics and gastroparesis therapeutics. It has little presence in nootropic contexts because it was optimized for peripheral gut activity rather than central penetration.